Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption

Summary

Purpose:

The overall objective of this study is to learn more about the disease chronic pancreatitis and thus contribute to better treatments. The investigators will gain this by studying the effects of vitamin D in the body immune system and bones. The investigators will also study the uptake of vitamin D through the intestine compared with the amount of vitamin D obtained through exposure to UVB rays.

The investigators have set a series of questions which the investigators want to answer with this experiment:

Do patients with chronic pancreatitis have reduced absorption of vitamin D from the gut?

* Have the two treatment methods with vitamin D, UV radiation and tablets, the same success rate?
* Does the distribution of the white blood cells change when the vitamin D level increases and does it depend on whether the patient have UVB radiation or tablet with vitamin D?
* Will patients require reduced amounts of painkillers when vitamin D level increases?
* Does vitamin D have influence on blood sugar and thus the risk of diabetes or worsening of this?
* Could vitamin D affect the blood content of inflammation markers?
* Does the patient feel better when he takes vitamin D?
* Does bone strength increase when the patients receive grants of vitamin D?

Conditions

• Chronic Pancreatitis
• Malabsorption Syndromes

Interventions

DRUG

Calcium, Dietary

400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.

DRUG

Cholecalciferol

38 micrograms daily. Week 0-10.

RADIATION

UVB

Ultraviolet radiation type B administered in a tanning bed. One time weekly.

RADIATION

UV-filtered light.

Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.

DRUG

Cholecalciferol

38 micrograms daily. From week 14 to 52.

Sponsors & Collaborators

• Hvidovre University Hospital

  lead OTHER

Principal Investigators

• Jens-Erik B Jensen, Ph.d. · Dept. of osteoporosis, Hvidovre Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-12-31

Primary Completion

2010-05-31

Completion

2011-03-31

Countries

• Denmark

Study Locations